ArticleDigestive diseases and sciences2023
Impact of Sarcopenia on Clinical Course of Inflammatory Bowel Disease in Korea.
Article in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.
- Evaluating the role of sarcopenia in adverse clinical outcomes for Crohn's disease patients: a systematic review and meta-analysis.International journal of colorectal disease · 2025Pooled it
- Assessing causality between inflammatory bowel diseases with frailty index and sarcopenia: a bidirectional Mendelian randomization study.European journal of medical research · 2024Pooled it
- Sarcopenia in Inflammatory Bowel Disease: Prevalence, Mechanisms, Detection, Adverse Clinical Impact and Targetable Care Gaps-A Narrative Review Supported by a Structured Literature Search.Life (Basel, Switzerland) · 2026Review
- Beyond Adiposity: Lean Mass Phenotyping and Adipokine Interpretation in Pediatric Crohn's Disease.Digestive diseases and sciences · 2026Article
- Gut, bone, and muscle: the triad of osteosarcopenia in inflammatory bowel disease.Intestinal research · 2025Review
- HISLIS: Histology, Sarcopenia, and Lung Inflammation Score-A New Perspective for Lung Cancer Patients?Life (Basel, Switzerland) · 2025Article
- Predictive model for sarcopenia in patients with non-small cell lung cancer and malignant pleural effusion.BMC cancer · 2025Article
- The effects of sarcopenic obesity on immediate postoperative outcomes after pancreatoduodenectomy: a retrospective cohort study.Annals of surgical treatment and research · 2024Article
- Assessment of body composition-related imaging parameters indicative of sarcopenia in Chinese patients with Crohn's disease: correlation with disease severity and biologic efficacy.American journal of translational research · 2024Article
- Sarcopenia and frailty in inflammatory bowel disease: Emerging concepts and evidence.JGH open : an open access journal of gastroenterology and hepatology · 2024Review
- The relationship between inflammatory bowel disease and sarcopenia-related traits: a bidirectional two-sample mendelian randomization study.Frontiers in endocrinology · 2024Article
- Myopenia and body fat distribution in hospitalized ulcerative colitis patients: correlations with clinical characteristics and response to vedolizumab.Frontiers in nutrition · 2024Article
- Diagnostic Criteria and Prognostic Relevance of Sarcopenia in Patients with Inflammatory Bowel Disease-A Systematic Review.Journal of clinical medicine · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsReduced body muscle mass is a poor prognostic factor for inflammatory bowel disease (IBD). In this study, we investigated the prevalence of sarcopenia at diagnosis and its clinical significance in Korean patients with IBD.
methodsThe prevalence of sarcopenia in IBD patients between June 1989 and December 2016 was investigated using a well-characterized referral center-based cohort. Abdominopelvic computed tomography within six months from IBD diagnosis was used for the evaluation. Sarcopenia was defined as an L3 skeletal muscle index of < 49 cm
resultsA total of 1,027 patients (854 Crohn's disease [CD]; 173 ulcerative colitis [UC]) were evaluated. Sarcopenia was found in 56.8% of the population (CD, 57.5%; UC, 53.2%), and male were more likely to be sarcopenic (CD, 94.3%; UC, 91.6%). There were no significant differences in the cumulative risk of using steroids, immunomodulators, biologics, and bowel resections (or colectomy) with or without sarcopenia during follow-up (median: CD, 5.8 years; UC, 3.7 years). In sarcopenic patients with CD, there was a significantly higher cumulative risk of perianal surgeries than in non-sarcopenic patients with CD (Log-rank test; P = 0.001). However, the risk of perianal surgeries was not significant in multivariate analysis (Odds ratio 1.368; 95% confidence interval 0.782-2.391; P = 0.272).
conclusionSarcopenia at diagnosis may have no significant prognostic value for medical treatment and bowel resection, but it may be associated with perianal CD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.